What's hot amongst the up and coming CAR-T cell therapies in early development?
Which Thunderbirds are Go in this niche?!
Going beyond gene edited CARs
A smorgasbord of bispecifics and CAR-T cells for autoimmune diseases
Reflections on how to overcome hurdles associated with CAR-T cell resistance
Are there hideen treasures in Yokohama, Japan
Teasing out relevant markers and learning more about what patients tumours are telling us is key
It's time to challenge our thinking on cytokines
Will new developments in tackling cytokines fare better in the clinic than the first generation attempts?
It's beginning to look a lot like Christmas...
The Yin and Yang of NK and T cells and how this can impact therapies
How a competitive landscape can change drastically over a short time
A look at the potential missing piece in making bispecifics even better
W2W4 at SITC23 - 10 emerging areas to pay attention to in IO
Eight key areas to watch out for at SITC 2023!
What do three phase 1 and one phase 2 trials tell us about future development?
In a few years time the next generation CAR-T cell therapies are going to look and behave very…
Improving cell therapy performance with a multitude of innovative strategies
Ten emerging development areas to watch out for in oncology during 2023
10 early stage IO biotechs to watch out for
Five areas of early stage IO developments to watch out for
What can we learn from a raft of early cell therapy companies with novel or intriguing approaches?
New CAR-T cell developments in solid tumours - hit or miss?
Looking beyond the hype from a broader perspective
Can you have your immune cake and eat it?
SITC 2021 Preview
The trials and tribulations of targeted agents in developmental therapeutics
A look at the first anti-cancer therapy with a radiopharmaceutical in advanced prostate cancer
Who's going to the masquerade ball and how might they fare in the future?
Hidden early stage gems to watch out for at ASCO21
New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.
13 ways in which CAR based or gene therapies can improve on current approaches to cell therapies
A look at switchable CAR-T cell therapies, plus CARs based on alternative immune cells.
Noteworthy AACR21 on-demand presentations.
Commentary on Day 1 at ESMO20 and data presented in the mini oral sessions
Five IO areas in early stage development to watch out for at ESMO20
Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...
Will we have more success targeting IL-18 to boost anti-tumour immunoty than other cytokines?
There are some creative and innovative new CAR T cell therapy designs being developed - what are they and where will they be tested?
Review of 12 posters that caught our attention in the ePoster Hall at ASGCT20
Ten intriguing novel agents in early development to watch out for
Some immune cells overlap in cancer and Covid-19 so what can we learn from them in order to make an impact?
Analysis and commentary of Nektar's IL-2 cytokine bempeg in combination with nivolumab in 1L advanced melanoma
What can we learn from biomarkers and immune profiling in patients receiving bempeg, a CD122-directed pegylated IL-2 therapy
How is Synthorx's IL-2 cytokine THOR-707 different from other compounds in this niche?
How the design of different cancer approaches can affect clinical performance
Can we employ red blood cells in allogeneic, off-the-shelf cellular therapy products for the treatment of cancer?
New insights emerging from research on cytokines as an effective way to induce anti tumour immunity
What is old is new again - a look at some forgotten oncology targets that are coming back in fashion
Update on PIVOT-02 with nivolumab plus NKTR-214 in 1L metastatic melanoma
Lessons learned from recent failure and a look at where a few new developments might be coming from...
On launched products, armored CARs and the potential threat from China
Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.
The latest part in our cytokine mini-series explores the potential for incorporating them in CARs or combining with checkpoint blockade through the lens of an expert in the field...
What can we learn from the updated Nektar NKTR-214 data presented at #ASCO18?
A look at various lessons from recent IO trials and how they can applied to new readouts expected at ASCO18
A look at how basic and translational evidence points towards TGFβ as a possible new target for IO combos in some tumour types
A look at one way with which we can target the tumour microenviroment to improve response of cancer immunotherapy
A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies
A look at innate approaches to stimulating the immune system including IL-15 agonists
A look at Nektar's promising IO portfolio and what's next for the up and coming biotech
Final SITC17 Preview and a look at key talks now that the abstracts are available.
Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline
Without effector T cells in the tumour, checkpoints won't work. So how do we attract more in? Here's one way to do it...
